![Figure 1. TCD STAT1−/− BM prevents DLI-induced GVHD. All recipients received a miHA-mismatched alloHSCT from either STAT1+/+ or STAT1−/− BM (129 → C3H.SW). Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 TCD STAT1+/+ BM or STAT1−/− BM on day +0. On day +14, 20 × 106 DLI was administered to induce GVHD. Some recipients did not receive a DLI as a negative GVHD control. All mice were followed for (A) clinical GVHD scores. On day +28, all groups were euthanized and immune reconstitution of (B) B cells and (C) Tregs in the spleen was ascertained by flow cytometry. (D) Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 STAT1−/− BM on day +0. On day +14, 0, 10, 20, or 40 × 106 DLI was administered to induce GVHD. Mice were followed for GVHD-associated weight loss. On Day +40, weight loss was compared, and (E) Treg expansion in the spleen was ascertained by flow cytometry. (F) Lethally irradiated recipients received a miHA-mismatched alloHSCT from STAT1+/+ BM (B6 → C3H.SW) treated with vehicle (phosphate-buffered saline [PBS]) or Exenatide (Ex4) for 3 days before alloHSCT. BM recipients continued to receive vehicle or Exenatide for 10 days after alloHSCT. 20 × 106 DLI was administered on day +14 to induce GVHD, and recipients were followed for clinical GVHD scores, and (G) % change in weight was compared at day +40. N = 3 to 7 mice/group, data are representative from 1 of 2 similar experiments. *P < .05, **P < .01, ***P < .001.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/124/12/10.1182_blood-2013-05-500876/4/1976f1.jpeg?Expires=1724242610&Signature=jJtfqUFzgGKk5pgJcymqLE5dwnlUAE0CWsM4XzKzl4YmkdQpssTr~pxZw2aZfSH5C8c24Ckcv7cLDChOTq805JAjzFnjSXmpt3hKYIyIO4AmOIdif3cFeinBXqcv~IL2IWgxMPJqxQtUNCFzxDBRss38ypjDeBKFJs5ShcWksHmL0eRPPdlyEoAyaN6f5aX8fea1ftwMaaKz4d8cKEG7Bkdpbx612RLny3nu4CKQuP1rhyF8pOodrsCSzS1MM7QoQPEC1EqadSxEdeaC~Vr8gcaattFNSmWm4mhomCNknqqlGGkOak1R0aC5QfK0TUs-q2V6LVxy41mwaYUJGfxlrQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TCD STAT1−/− BM prevents DLI-induced GVHD. All recipients received a miHA-mismatched alloHSCT from either STAT1+/+ or STAT1−/− BM (129 → C3H.SW). Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 TCD STAT1+/+ BM or STAT1−/− BM on day +0. On day +14, 20 × 106 DLI was administered to induce GVHD. Some recipients did not receive a DLI as a negative GVHD control. All mice were followed for (A) clinical GVHD scores. On day +28, all groups were euthanized and immune reconstitution of (B) B cells and (C) Tregs in the spleen was ascertained by flow cytometry. (D) Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 STAT1−/− BM on day +0. On day +14, 0, 10, 20, or 40 × 106 DLI was administered to induce GVHD. Mice were followed for GVHD-associated weight loss. On Day +40, weight loss was compared, and (E) Treg expansion in the spleen was ascertained by flow cytometry. (F) Lethally irradiated recipients received a miHA-mismatched alloHSCT from STAT1+/+ BM (B6 → C3H.SW) treated with vehicle (phosphate-buffered saline [PBS]) or Exenatide (Ex4) for 3 days before alloHSCT. BM recipients continued to receive vehicle or Exenatide for 10 days after alloHSCT. 20 × 106 DLI was administered on day +14 to induce GVHD, and recipients were followed for clinical GVHD scores, and (G) % change in weight was compared at day +40. N = 3 to 7 mice/group, data are representative from 1 of 2 similar experiments. *P < .05, **P < .01, ***P < .001.
